XML 54 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1

Collaboration Agreements - Ipsen Collaboration (Details) - USD ($)	1 Months Ended	3 Months Ended			9 Months Ended		12 Months Ended	23 Months Ended
	Feb. 29, 2016	Sep. 28, 2018	Mar. 30, 2018	Sep. 29, 2017	Sep. 28, 2018	Sep. 29, 2017	Dec. 28, 2018	Dec. 29, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues		$ 225,397,000		$ 152,510,000	$ 625,224,000	$ 332,405,000
Licenses
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues		51,323,000		54,335,000	152,261,000	74,706,000
Collaborative Arrangement with Ipsen
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment(s)	$ 210,000,000
Milestone payments earned								$ 125,000,000
Additional milestone achievement	194,000,000
Contingent cash receipts (up to)	520,300,000
Revenues		57,186,000		$ 50,679,000	$ 145,038,000	$ 60,703,000
Research and development arrangement performed for others, reimbursement for costs incurred, percent					35.00%
Collaboration period to achieve specified levels of commercial performance					10 years
Remaining performance obligation		53,400,000			$ 53,400,000
Net contract asset		24,500,000			$ 24,500,000
Collaborative Arrangement with Ipsen | GlaxoSmithKline
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalty on net sale					3.00%
Collaborative Arrangement with Ipsen | Initial and Second
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty tier					$ 150,000,000
Collaborative Arrangement with Ipsen | Initial and Second | Minimum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalty on net sale					22.00%
Collaborative Arrangement with Ipsen | Initial and Second | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalty on net sale					26.00%
Collaborative Arrangement with Ipsen | Initial
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalty on net sale					2.00%
Collaborative Arrangement with Ipsen | Second
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalty on net sale					12.00%
Collaborative Arrangement with Ipsen | EMA Approval - RCC
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Additional milestone achievement		50,000,000			$ 50,000,000
Revenues		36,900,000			36,900,000
Collaborative Arrangement with Ipsen | Health Canada Approval
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net sales achievement level					5,000,000
Collaborative Arrangement with Ipsen | Net Sales Achievements
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments earned					25,000,000
Net sales achievement level					100,000,000
Collaborative Arrangement with Ipsen | HCC Acceptance
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Additional milestone achievement	$ 40,000,000
Collaborative Arrangement with Ipsen | Licenses | EMA Approval - RCC
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues		$ 200,000	$ 45,800,000
Collaborative Arrangement with Ipsen | Licenses | EMA Approval - RCC | Forecast
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues							$ 40,000,000
Collaborative Arrangement with Ipsen | Licenses | EMA Approval
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues					$ 46,200,000

X

- Definition

Collaborative Arrangement, Achievement Levels of Commercial Performance, Period

+ References

No definition available.

+ Details

Name:	exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod
Namespace Prefix:	exel_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement

+ References

No definition available.

+ Details

Name:	exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Maximum amount eligible for commercial milestones under collaborations agreement.

+ References

No definition available.

+ Details

Name:	exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Milestone Payments Earned

+ References

No definition available.

+ Details

Name:	exel_MilestonePaymentsEarned
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Milestone Payments, Minimum Net Sales Achievement Amount

+ References

No definition available.

+ Details

Name:	exel_MilestonePaymentsMinimumNetSalesAchievementAmount
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Percent of royalty on net sale.

+ References

No definition available.

+ Details

Name:	exel_PercentOfRoyaltyOnNetSale
Namespace Prefix:	exel_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent

+ References

No definition available.

+ Details

Name:	exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent
Namespace Prefix:	exel_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Royalty Tier

+ References

No definition available.

+ Details

Name:	exel_RoyaltyTier
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Upfront Payment(s)

+ References

No definition available.

+ Details

Name:	exel_UpfrontPayments
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044

+ Details

Name:	us-gaap_ContractWithCustomerAssetNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	exel_RoyaltytierAxis=exel_FinalTierMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	exel_RoyaltytierAxis=exel_InitialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	exel_RoyaltytierAxis=exel_SecondMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	exel_MilestoneObjectiveAxis=exel_EMAApproval1LRCCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	exel_MilestoneObjectiveAxis=exel_HealthCanadaApprovalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	exel_MilestoneObjectiveAxis=exel_RevenueAchievementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	exel_MilestoneObjectiveAxis=exel_EMAApprovalHCCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	exel_MilestoneObjectiveAxis=exel_EMAApprovalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: